Genomind To Exhibit At 2014 NEI Psychopharmacology Congress

Genomind To Exhibit At 2014 NEI Psychopharmacology Congress

Attendees will have opportunities to discover the influence of the Genecept™ Assay

CHALFONT, PA – November 12, 2014 – Genomind, a personalized medicine company, is excited to announce that they will exhibit at the 2014 NEI Psychopharmacology Congress, being held November 13-16, 2014, in Colorado Springs, CO.

Genomind will be available on the main show floor at Booth #122 to connect with clinicians and industry experts, showcase our groundbreaking Genecept Assay, and educate medical professionals on our dedication to harnessing the latest research to better treat patients.

Genomind will be presenting a poster, “Pharmacogenetic Testing Shows Utility for Psychiatric Patients”

The NEI Congress is designed to promote the latest research, advancements, and treatment strategies for a range of mental illnesses, including ADHD, anxiety disorders, bipolar disorder, depression, and schizophrenia. NEI is recognized as a leader in quality education, having received the Accreditation Council for Continuing Medical Education’s “Accreditation with Commendation in 2013” and approval from the American Society for the Advancement of Pharmacotherapy to provide continuing education credits for primary care physicians, nurse practitioners, psychologists, and pharmacists.

About the Genecept Assay

The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit

About Genomind

Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at

For more information, contact:

Adam Shapiro

Amy Pressman
Marketing Manager, Genomind


} ); } ( jQuery ) );